Binimetinib is indicated for:
Irrespective of gender only Adults (18 years old or older)
Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
For this indication, the medical literature mentions below treatments (click for details):
Active ingredient Binimetinib is contraindicated in the following cases: